Kornimate/medical-research-clean huggingface dataset:
study on the peristaltic direction of gi anastomosis in roux-en-y reconstruction

Conditions: Peristaltic Direction; Roux-en-Y Gastrointestinal Anastomosis; Gastric Cancer

Summary: the aim of this study is intending to provide the optimal procedures of the peristaltic direction of gastrointestinal anastomosis in roux-en-y reconstruction after distal curative gastrectomy for gastric cancer, which can provide the best operation mode of roux-en-y anastomosis in digestive tract reconstruction during distal gastrectomy for reducing postoperative complications and improving quality of life for patients.

in this study, all 148 the included patients will underwent the distal curative gastrectomy for gastric cancer and will be performed the roux-en-y reconstruction for gastrointestinal anastomosis. of them, 74 patients will be randomized in the group undergoing with the isoperistaltic anastomosis in the roux-en-y reconstruction procedure. meanwhile, the other 74 cases will be randomized in the group undergoing with the antiperistaltic anastomosis in the roux-en-y reconstruction procedure. then, we will evaluate the differencies of effects of early recovery postoperatively (exhaust, defecation, eating, residual stomach peristalsis, length of hospital stay, etc.) and late gastrointestinal effects (bile reflux, residual gastritis, gastric emptying function, etc.) between above two group of patients, which will make an important contribution to reduce medical costs and potential improvements of the prognosis after distal curative gastrectomy for gastric cancer.

Eligibility criteria:
inclusion criteria: * 1) pathological examination confirmation the adenocarcinoma of stomach before surgery * 2) physical conditions compliance with the requirements for curative gastrectomy * 3) consent to undergo the d2 lymphadenectomy, and the dissected proportion of stomach no less than 2/3 * 4) comply with the protocol during the whole study period * 5) no neoadjuvant therapy administration * 6) sign informed consent and permission of withdraw in the whole study period * 7) consent to provide the tissue specimens after surgery for this study * 8) estimation the overall survival after surgery no less than 6 months * 9) no anesthesia or operation contraindication disease * 10) ct1-4n0-2m0 stage demonstration by ct and endoscopic ultrasonography examinations * 11) negative cytological detection in operation * 12) no seriously concomitance's diseases * 13) karnofsky performance scores (kps) more than 60 * 14) examined lymph node count no less than 16 exclusion criteria: * 1) women during pregnant stage and breast-feed stage * 2) women of childbearing age without any contraceptive measures * 3) severe congestive heart failure, frequent arrhythmia, or myocardial infarction within 12 months * 4) immunosuppressive therapists for organ transplantation * 5) seriously uncontrolled recurrent infection * 6) other malignant tumors * 7) no abilities of self-knowledge or mental disorders * 8) participating in other clinical trials * 9) siewert i and ii esophagogastric junction tumors * 10) serious internal diseases obstruction surgery
the effect of inspiratory muscle training in post covid-19 patients

Conditions: Covid19; Infective Pneumonia

Summary: the covid-19 infection, which is considered as a pandemic by the world health organization, affects the whole world. covid-19 is an infectious respiratory disease caused by sars-cov-2. it is stated in early studies that after covid-19 infection, there are adverse effects on both the peripheral and respiratory muscles along with the pulmonary system involvement. the purpose of our study; to examine the effect of inspiratory muscle training (imt) on respiratory muscle strength, respiratory functions and functional capacity in postcovid-19 patients. patients who have been hospitalized and discharged with the diagnosis of covid-19 in istinye university hospitals, at least 6 weeks have passed since the infection, the pcr test has turned negative will be taken. the evaluation and treatment of the patients will be carried out in the education and research units of istinye university physiotherapy and rehabilitation department. patients included in the study will be randomly divided into two groups, study and control groups. demographic evaluation form, post covid functional status scale, charlson comorbidity index, modified medical research council (mmrc) dyspnea scale, corbin posture analysis, respiratory function test, respiratory muscle strength measurement, respiratory muscle endurance measurement, 6-minute walking test (6 mwt) ), peripheral muscle strength, grip strength, hospital anxiety and depression scale (hads), breathlessness perception questionnaire (bbq) and nottingham health profile questionnaire will be used. in the study group, imt will be applied at 40% of the maximum inspiratory pressure (mip) for eight weeks, every day of the week, twice a day for 15 minutes. the patients will come for a control once a week, the mip values will be measured again and the new training intensity will be determined at 40% of the new mip value. the control group will be given a constant training of 15 minutes at 10% of the mip, twice a day, every day of the week for eight weeks. evaluations of the study and control groups will be made at the beginning and after eight weeks.


Eligibility criteria:
inclusion criteria: * adults ages 18-70 * being clinically stable, * having covid-19 infection and at least 6 weeks after infection * being between grade 2-4 according to post-covid functional status scale * regular participation in treatment * to read, write and understand turkish * volunteering to participate in research exclusion criteria: * presence of mental and cognitive impairments * having an orthopedic, neurological disease that prevents exercise * uncontrolled hypertension, having a cardiovascular disease * pregnancy and breastfeeding

Keywords: inspiratory muscle training post-covid 19 respiratory muscle strength respiratory function functional capacity
mhealth intervention to increase physical activity in prediabetes and type 2 diabetes

Conditions: Type 2 Diabetes; PreDiabetes

Summary: sedentary behaviour has a detrimental effect on the mortality, morbidity, and well-being of patients with type 2 diabetes and prediabetes, and general practitioners should advise patients on how to self-monitor and increase their physical activity. the emergence of mobile health (mhealth) technologies unlocks the potential to further improve physical behaviour using an innovative "just-in-time" adaptive approach whereby behavioural support is provided in real-time, based on data from wearable sensors. thus, the investigators aim to evaluate the effect of a just-in-time mhealth intervention administered by general practitioners on the physical activity and sedentary behaviour of patients with type 2 diabetes and prediabetes. a total of 340 patients will be recruited from 20 general practices across the czech republic and randomly assigned to either an active control or intervention group. both groups will receive brief physical activity advice from their general practitioners and a fitbit fitness tracker to self-monitor their daily steps, but the intervention group will also receive a mhealth-enabled just-in-time adaptive intervention and regular monthly phone counselling in the first 6 months. the mhealth intervention will be delivered using a custom-developed system (healthreact) connected to the fitbit that will trigger just-in-time text messages. for example, a prompt to take a break from sedentary behaviour will be triggered after 30 sedentary minutes or a motivational message with a specific goal to take more steps will be triggered when the total step count is too low. the primary outcome will be the change in daily step count at 6 months, other outcomes include changes in other physical behaviour measures, blood tests, anthropometry and patient-reported outcomes at 6 and 12 months. if the intervention is effective, this study will provide a model of health prevention that can be directly implemented and commissioned within primary care using existing infrastructure.


Eligibility criteria:
inclusion criteria: * diagnosis of prediabetes or t2dm according to the czech guidelines for gps on diabetes mellitus1 and prediabetes2, i.e. fasting plasma glucose 5.6-6.9 mmol/l, or 2-h plasma glucose of 7.8-11.0 mmol/l after ingestion of 75 g of oral glucose load for the diagnosis of prediabetes, and fasting plasma glucose ≥ 7.0 mmol/l, or 2-h plasma glucose ≥ 11.1 mmol/l after ingestion of 75 g of the oral glucose load for the diagnosis of t2dm * age 18 years or older. * registered at a participating general practice. * regular users of a smartphone and willing to use it as part of the study. * written informed consent obtained before any assessment related to the study. exclusion criteria: * unable to walk * pregnancy * taking insulin * living in a residential or nursing care home * co-morbid conditions that would affect their adherence to the trial procedures
comparative effects of conventional physical therapy, kinesio taping and eswt in upper trapezius mps.

Conditions: Trapezius Muscle Strain

Summary: there is no study in the literature comparing both kinesiotaping and extracorporeal shock wave therapy (eswt) with conventional physical therapy in upper trapezius myofascial pain syndrome. in this study, we aimed to make this comparison.


Eligibility criteria:
inclusion criteria: * presence of at least 1 active trigger point in the upper trapezius muscle, exacerbation of pain when this point(s) is pressed, painful limitation of cervical lateral flexion and extension. exclusion criteria: * having a history of spine and upper extremity surgery, neuromuscular disease, active rheumatologic disease, active infection, malignancy, having previously applied eswt or kinesio taping to the back and neck region.
mri radiomics assessing neoadjuvant chemotherapy in breast cancer to predict lymph node metastasis and prognosis(rbc-02)

Conditions: Invasive Breast Cancer; Neoadjuvant Chemotherapy; Radiomics; Axillary Lymph Node; Prognosis

Summary: this study is aimed to illustrate whether radiomics combining multiparametric mri before and after neoadjuvant chemotherapy (nact) with clinical data is a good way to predict axillary lymph node metastasis and prognosis in invasive-breast-cancer.

this study proposes to build a clinical predictive model to predict axillary lymph node metastasis and prognosis in invasive-breast-cancer patients who received neoadjuvant chemotherapy before surgery. the model is built based on breast mri signatures extracted and analyzed via deep machine-learning algorithm methods. invasive breast cancer patients undergo multiparametric mri at baseline, then undergo multiparametric mri after received neoadjuvant chemotherapy for at least 4 cycles as planned. after the surgery, responses to neoadjuvant chemotherapy are determined according to the histopathologically examination of the surgically resected specimens. after completion of treatment procedure, patients are followed up for 5 years.

Eligibility criteria:
inclusion criteria: 1. primary lesion diagnosed as invasive breast cancer; 2. imaging examination confirmed no distant organ metastasis; 3. received neoadjuvant chemotherapy for drugs such as taxanes, anthracyclines, and platinum as planned; 4. completed breast mri examination before or after neoadjuvant chemotherapy; 5. accepted breast cancer surgery and axillary lymph node dissection; 6. eastern cooperative oncology group performance status 0-2. exclusion criteria: 1. history of ipsilateral axillary or breast surgery; 2. inflammatory breast cancer; 3. bilateral breast cancer; 4. malignant tumor history in 5 years; 5. patients with cervical or contralateral axillary lymph node metastasis; 6. incomplete imaging or medical history data.

Keywords: invasive breast cancer neoadjuvant chemotherapy radiomics axillary lymph node metastasis survival machine learning analysis
the reproducibility and clinical utility of an abbreviated fat tolerance test

Conditions: Dyslipidemias; Metabolic Syndrome

Summary: this study aims to evaluate the reliability of a shortened fat tolerance test ("abbreviated fat tolerance test", or "aftt") for measuring post-meal lipids in human blood. the reliability of the triglyceride results in this test are compared to the reliability of the glucose results from an oral glucose tolerance test (ogtt), a widely-used and clinically accepted metabolic test.


Eligibility criteria:
inclusion criteria: * free of chronic disease * normal (healthy) fasting glucose and triglycerides exclusion criteria: * presence of pace-maker * pregnant * using tobacco products * using medications or dietary supplements that could modify primary outcomes
vagus nerve stimulation(vns) as treatment for fibromyalgia patients

Conditions: Fibromyalgia

Summary: fibromyalgia (fm) is a syndrome with clinical symptoms involving multiple systems. the efficacy of current treatments is inadequate, and more alternative modalities are needed for the management of fm patients. the parasympathetic vagus nerve innervates and integrates sensory, motor, and autonomic systems and has been suggested to play a role in pain modulation. the role of vagus nerve stimulation (vns) as a treatment option for fm patients is yet to be investigated. the investigators propose to examine the hypothesis that vagus nerve stimulation could improve pain and related comorbid symptoms for fm patients.

the main goal of this study is to generate preliminary data on the effect of vns on fm symptoms. specifically, the investigators will utilize a recently developed, non-invasive method of tvns (transcutaneous vns) via auricular branches of vagus nerve (abvn). the investigators plan to conduct an 4-week clinical study with 60 subjects randomized into 2 groups(tvns group and control group; 30 subjects in each group). the primary outcome measure will be pain intensity. the secondary outcome measures will be fatigue, sleep, and other health-related quality of life measure. these outcome measures will be made at baseline week 0 (before any intervention), and at the end of 4 weeks.

Eligibility criteria:
inclusion criteria: 1. subject is 18 to 80 years old, including both male and female subjects. 2. subject has a documented diagnosis of fm for at least three months. this requirement is to avoid the uncertainty of an unstable pain condition and to minimize the study variation. 3. subject has a pain score of 4 or above (numeric pain score: 0 - 10 from no pain to worst pain). exclusion criteria: 1. subject has current cardiac arrhythmia or had implanted cardiac pacemaker or aicd device. 2. subject has major psychiatric disorder required hospitalization in the last 3 months. 3. subject has active infection at the site of device application. 4. subject has recurrent syncope symptoms within the past three months. 5. subject is pregnant. 6. subject has had vns treatment within the past two months. .

Keywords: vagus nerve stimulation, pain fibromyalgia symptoms
study of perioperative dostarlimab in participants with untreated t4n0 or stage iii dmmr/msi-h resectable colon cancer

Conditions: Colonic Neoplasms; Neoplasms, Colon

Summary: the primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (soc) in participants with untreated t4n0 or stage iii (resectable), defective mismatch repair/ microsatellite instability high (dmmr/msi-h) colon cancer.


Eligibility criteria:
inclusion criteria: * has untreated pathologically confirmed colon adenocarcinoma * has resectable colon adenocarcinoma defined as clinically t4n0 or stage iii * has radiologically evaluable disease * has a tumor demonstrating the presence of either dmmr status or msi-h exclusion criteria: * has distant metastatic disease. * has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of colon cancer * has a tumor that, in the investigator's judgment is causing symptomatic bowel obstruction or otherwise requires urgent/emergent surgery * has undergone any major surgical procedure, open biopsy, or experienced significant traumatic injury within 28 days prior to randomization * has any history of interstitial lung disease or pneumonitis * has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice * has a history of allogenic stem cell transplantation or organ transplantation * is receiving any other anticancer or experimental therapy. no other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participant is receiving study intervention * is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the study * has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known allergies to dostarlimab, or its excipients, or any components of folfox or capeox

Keywords: jemperli dostarlimab dostarlimab-gxly tsr-042 gsk4057190a folfox capeox colon cancer resectable colon cancer dmmr/msi perioperative neoadjuvant adjuvant
r-wave optimisation in cardiac resynchronisation therapy study

Conditions: Heart Failure, Systolic

Summary: the aim of this study is to investigate whether the use of a simple feature on the 12 lead electrocardiogram (ecg) to optimise pacemaker device programming can have clinically relevant benefit to patient management. more specifically it is to investigate whether using the r-wave in v1 of the surface ecg to guide the timings between left (lv) and right ventricular (rv) pacing improves response to cardiac resynchronisation therapy.


Eligibility criteria:
inclusion criteria * the patient must have a biventricular pacemaker in situ, implanted for nyha class iii / iv heart failure syndrome with impaired systolic function. * implantation indication must have included a left ventricular ejection fraction measured on transthoracic echo of \<35% and either * a qrs duration of \>150ms or * a qrs duration of 120 - 149ms with further evidence of dyssynchrony confirmed by echocardiography. * participants must have \>95% true biventricular pacing over the 1 month before enrolment and throughout the observation period. * the biventricular paced qrs complex morphology in lead v1 of subject's standard 12 lead surface ecg must show an r wave height of \< 1mm or \<20% of the total qrs deflection with standard lv offset settings applied. * the subject's standard 12 lead surface ecg must show a right bundle branch block pattern in lead v1 during lv only pacing. * the participant must be willing to comply with the protocol requirements including travelling to the royal bournemouth hospital for the attendances required for the study and intend to have their long term device follow up at the royal bournemouth hospital at the time of enrolment. * provision of informed consent exclusion criteria * hypertrophic or restrictive cardiomyopathy * suspected acute myocarditis * correctable valvulopathy * an acute coronary syndrome within the last 3 months * recent (within the last 3 months) or scheduled coronary revascularisation * treatment resistant hypertension * severe obstructive lung disease * pregnancy at the time of enrolment or a desire to become pregnant during the study period * an inability to walk * reduced life expectancy not associated with cardiovascular disease (less than 1 year) * unable to provide informed consent

Keywords: heart failure cardiac resynchronisation therapy biventricular pacemaker optimisation
a trial to explore acceptance and performance of using a digital medicine system with healthcare professionals and adults with schizophrenia, schizoaffective disorder, or first episode psychosis on an oral atypical antipsychotic

Conditions: Schizophrenia; Schizoaffective Disorder; First Episode Psychosis

Summary: digital medicine systems (dms) have been designed to assist individuals with the management of their daily health, wellness, and medication use. the dms is being developed as a healthcare management tool to precisely measure medication adherence and to potentially enhance adherence.

the advancements in the treatment of mental health patients with dms will enable healthcare professionals to assess suboptimal adherence and make more informed treatment decisions. in addition to these improvements, it will also provide a platform for engagement between participants, healthcare professionals, and caregivers/support persons. participants who entered the trial were treated with one of the oral atypical antipsychotics defined in the trial (aripiprazole, olanzapine, quetiapine, or risperidone \[though no participant took risperidone in this trial\]). the treatment medication decision was determined by the healthcare professionals.

Eligibility criteria:
inclusion criteria: * participant was prescribed aripiprazole, olanzapine, quetiapine, or risperidone. * participant possessed a smartphone, or a smartphone provided by the sponsor, and was willing to download and interact with the dms app. * skin on the anterior chest just above the lower edge of the rib cage was free of any dermatological problems (for example, open wounds, warts, rashes, atopic dermatitis). exclusion criteria: * participant with a known allergy to adhesive tape or any pertinent components of the patch or coe product. * prisoners could not be enrolled into this trial. * participant who was hospitalized due to mental or physical illness (inpatient) at the time of screening/baseline. * any participant who, through religious or lifestyle choices, would not take gelatin capsules. * female of childbearing potential who was breast-feeding and/or who had a positive pregnancy test result prior to receiving trial enrollment, or who planned to become pregnancy during the trial.

Keywords: digital medicine system
continuous enteral rehydration by nasogastric tube with ors in children with acute gastroenteritis

Conditions: Acute Gastroenteritis; Dehydration

Summary: when oral rehydration is impossible, enteral rehydration via the nasogastric route has been the recommended method of rehydration since 2008 by espghan ( european society for paediatric gastroenterology hepatology and nutrition ), for children with acute gastroenteritis. however, these recommendations are rarely followed in france. these recommendations were not applied in the children's emergency department of brest university hospital. the investigators changed the protocol and shared it with the caregivers of the emergency unit. the investigators studied the impact of this change of protocol

the main purpose was to assess the proportion of children rehydrated by nasogastric tube(ng) after protocol change. secondary outcomes were to assess hospital length of stay and sides effects. it is a retro and prospective study. the first phase took place from june to september 2018 and the second from june to september 2019. any child presenting to pediatric emergencies for acute gastroenteritis requiring nonoral rehydration was included.

Eligibility criteria:
inclusion criteria: any child presenting to pediatric emergencies for acute gastroenteritis requiring nonoral rehydration was included exclusion criteria: * acute gastroenteritis on return from tropical countries * child with endocrine system diseases requiring parenteral rehydration * history of chronic pathology requiring enteral feeding

Keywords: nasogastric tube emergency medicine pediatric medicine